Genfit S.A. (OTCMKTS:GNFTF) Short Interest Down 32.5% in August

Genfit S.A. (OTCMKTS:GNFTF) was the recipient of a large decline in short interest during the month of August. As of August 31st, there was short interest totaling 515 shares, a decline of 32.5% from the August 15th total of 763 shares. Based on an average daily trading volume, of 907 shares, the short-interest ratio is currently 0.6 days.

Genfit Price Performance

GNFTF stock remained flat at $15.75 during trading on Thursday. The stock’s 50 day moving average is $15.07 and its 200 day moving average is $11.96. Genfit has a 52 week low of $4.14 and a 52 week high of $16.50.

About Genfit

Genfit is a clinical‐stage biopharmaceutical company headquartered in Lille, France, specializing in the development of innovative therapies and diagnostics for liver and metabolic diseases. The company’s research and development efforts are primarily focused on non‐alcoholic steatohepatitis (NASH), a progressive liver disorder with significant unmet medical needs. Genfit’s lead therapeutic candidate, elafibranor, is designed to target key pathways involved in inflammation, fibrosis and lipid metabolism, positioning it as a potential treatment for patients with NASH and associated metabolic complications.

In addition to its therapeutic pipeline, Genfit has established a diagnostic arm centered on NIS4®, a proprietary blood‐based test that leverages transcriptomic biomarkers to enable earlier and more accurate detection of liver fibrosis in patients at risk for NASH.